Terry D Butters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4950098/publications.pdf

Version: 2024-02-01

567144 642610 1,535 25 15 23 citations h-index g-index papers 25 25 25 1765 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Structure of human endo- \hat{l} ±-1,2-mannosidase (MANEA), an antiviral host-glycosylation target. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29595-29601.	3.3	14
2	Inhibition of αâ€glucosidase activity by Nâ€deoxynojirimycin analogs in several insect phloem sap feeders. Insect Science, 2016, 23, 59-67.	1.5	5
3	Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca2+ stores. Virology, 2014, 462-463, 135-148.	1.1	32
4	Glycoprotein misfolding in the endoplasmic reticulum: identification of released oligosaccharides reveals a second ER-associated degradation pathway for Golgi-retrieved proteins. Cellular and Molecular Life Sciences, 2013, 70, 2799-2814.	2.4	20
5	Structural and mechanistic insight into N-glycan processing by endo-α-mannosidase. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 781-786.	3.3	74
6	Restricted processing of glycans by endomannosidase in mammalian cells. Glycobiology, 2012, 22, 1282-1288.	1.3	9
7	Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells. Glycoconjugate Journal, 2009, 26, 1109-1116.	1.4	19
8	Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase. Journal of Biological Chemistry, 2007, 282, 29052-29058.	1.6	109
9	Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders. Expert Opinion on Pharmacotherapy, 2007, 8, 427-435.	0.9	44
10	Gaucher disease. Current Opinion in Chemical Biology, 2007, 11, 412-418.	2.8	109
11	Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology, 2005, 15, 43R-52R.	1.3	204
12	Substrate reduction therapy in lysosomal storage diseases: a clarification. Nature Reviews Drug Discovery, 2004, 3, 98-98.	21.5	0
13	Miglustat: profile report. Drugs and Therapy Perspectives, 2004, 20, 5-7.	0.3	O
14	Miglustat. Drugs, 2003, 63, 2435-2436.	4.9	1
15	Small–molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 927-945.	1.8	58
16	Therapeutic Applications of Imino Sugars in Lysosomal Storage Disorders. Current Topics in Medicinal Chemistry, 2003, 3, 561-574.	1.0	156
17	Introduction:  GlycobiologyUnderstanding the Language and Meaning of Carbohydrates. Chemical Reviews, 2002, 102, 283-284.	23.0	92
18	Targeting glycosylation as a therapeutic approach. Nature Reviews Drug Discovery, 2002, 1, 65-75.	21.5	409

#	Article	IF	CITATIONS
19	Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases. Expert Reviews in Molecular Medicine, 2000, 2, 1-17.	1.6	12
20	Structural characterization of the N-linked oligosaccharides derived from HIVgp120 expressed in lepidopteran cells. Glycoconjugate Journal, 1998, 15, 83-88.	1.4	16
21	Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. Biology of the Cell, 1997, 89, 123-131.	0.7	3
22	Ultrastructural changes in the Golgi apparatus and secretory granules of HL-60 cells treated with the imino sugar N-butyldeoxynojirimycin. Biology of the Cell, 1997, 89, 123-131.	0.7	1
23	Evidence That N-Linked Glycosylation Is Necessary for Hepatitis B Virus Secretion. Virology, 1995, 213, 660-665.	1.1	88
24	Inhibitors of Glycosphingolipid Biosynthesis Trends in Glycoscience and Glycotechnology, 1995, 7, 495-511.	0.0	38
25	Synthesis of 1,5-dideoxy-3-O-(α-D-mannopyranosyl)-1,5-imino-D-mannitol and 1,5-dideoxy-3-O-(α-D-glucopyranosyl)-1,5-imino-D-mannitol: Powerful inhibitors of endomannosidase. Tetrahedron: Asymmetry, 1993, 4, 2011-2024.	1.8	22